Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis.
injection
insurance claims
retrospective database study
surgery
Journal
ClinicoEconomics and outcomes research : CEOR
ISSN: 1178-6981
Titre abrégé: Clinicoecon Outcomes Res
Pays: New Zealand
ID NLM: 101560564
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
06
2020
accepted:
06
10
2020
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
13
11
2020
Statut:
epublish
Résumé
Studies examining differences in US healthcare resource utilization (HCRU) and associated healthcare costs between collagenase clostridium histolyticum (CCH) and fasciectomy for Dupuytren contracture (DC) are limited. This study evaluated US HCRU and direct healthcare cost for the treatment of DC in privately insured patients using insurance claims. This retrospective observational cohort study analyzed data from large nationwide insurance claims databases; it included individuals diagnosed with DC between July 1, 2011, and June 30, 2017, who were adults at index date (date of first treatment: CCH or fasciectomy). Participants had continuous health plan coverage 24 months pre-index and 12 months post-index date. All-cause and DC-related HCRU and healthcare costs from the payers' perspective were compared between propensity score-matched cohorts. Generalized linear models assessed factors associated with all-cause total healthcare costs. Of 83,983 patients diagnosed with DC, 1932 adults receiving fasciectomy and 953 adults receiving CCH were included. The mean ± standard deviation total all-cause healthcare cost was significantly lower with CCH than with fasciectomy (US$11,897 ± US$14,633 versus US$15,528 ± US$22,254, respectively; Based on matched cohort data, adjusted 1-year healthcare costs for CCH-treated individuals were significantly lower compared with costs for fasciectomy-treated individuals.
Identifiants
pubmed: 33177851
doi: 10.2147/CEOR.S269957
pii: 269957
pmc: PMC7649243
doi:
Types de publication
Journal Article
Langues
eng
Pagination
635-643Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Zah et al.
Déclaration de conflit d'intérêts
Vladimir Zah, Djurdja Vukicevic, and Martina Imro are employees of ZRx Outcomes Research Inc. (institution founded by Endo Pharmaceuticals to conduct the present analysis), and have received grants from Endo Pharmaceuticals Inc. Jovana Pelivanovic and Simona Tatovic were employed by ZRx Outcomes Research Inc. at the time of the study. Jane Ruby was employed by Endo Pharmaceuticals Inc. at the time of the study. David Hurley is an employee of Endo Pharmaceuticals Inc. The authors report no other potential conflicts of interest for this work.
Références
N Engl J Med. 2009 Sep 3;361(10):968-79
pubmed: 19726771
J Intern Med. 1993 Aug;234(2):189-93
pubmed: 8340742
J Hand Surg Am. 2010 Dec;35(12):2027-38.e1
pubmed: 21134613
J Bone Joint Surg Br. 1984 May;66(3):322-5
pubmed: 6725338
J Hand Ther. 2009 Jan-Mar;22(1):21-6; quiz 27
pubmed: 18986794
Chir Main. 2013 Apr;32(2):68-73
pubmed: 23507313
Hand (N Y). 2017 Jan;12(1):13-20
pubmed: 28082837
Pharmacoepidemiol Drug Saf. 2012 May;21 Suppl 2:69-80
pubmed: 22552982
J Hand Surg Am. 2013 Jun;38(6):1209-14
pubmed: 23707018
Lancet. 2003 Jul 12;362(9378):165-8
pubmed: 12867120
Hand Clin. 2018 Aug;34(3):307-314
pubmed: 30012291
Nat Rev Rheumatol. 2010 Dec;6(12):715-26
pubmed: 21060335
J Bone Joint Surg Br. 1997 Mar;79(2):206-10
pubmed: 9119843
BMC Musculoskelet Disord. 2013 Oct 14;14:293
pubmed: 24125161
Hand (N Y). 2011 Jun;6(2):149-58
pubmed: 21776198
J Hand Surg Asian Pac Vol. 2018 Sep;23(3):336-341
pubmed: 30282551
J Hand Surg Am. 2019 Nov;44(11):919-927
pubmed: 31537401
Surgeon. 2012 Jun;10(3):151-8
pubmed: 22297148
J Plast Reconstr Aesthet Surg. 2014 Mar;67(3):368-72
pubmed: 24486152
BMJ Open. 2014 Jan 15;4(1):e004166
pubmed: 24435894
Hand Surg. 2014;19(2):205-9
pubmed: 24875504
Health Technol Assess. 2015 Oct;19(90):1-202
pubmed: 26524616